Free tool
FAERS Monitor: Tagamet Hb
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020238 or its brand name (Tagamet Hb, Cimetidine). Reports on generic versions are filed under their own applications.
Reports
9,313
Serious
7,592
82% of reports
Hospitalization
3,450
Death reported
1,182
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- chronic kidney disease1,264
- acute kidney injury716
- nausea698
- renal failure694
- fatigue606
- drug ineffective510
- dyspnoea507
- vomiting493
- diarrhoea454
- pain439
- death403
- dizziness388
- off label use387
- headache373
- gastrooesophageal reflux disease369
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 351 |
| 2005 | 479 |
| 2006 | 351 |
| 2007 | 186 |
| 2008 | 275 |
| 2009 | 279 |
| 2010 | 321 |
| 2011 | 368 |
| 2012 | 647 |
| 2013 | 288 |
| 2014 | 222 |
| 2015 | 349 |
| 2016 | 348 |
| 2017 | 350 |
| 2018 | 685 |
| 2019 | 1,032 |
| 2020 | 599 |
| 2021 | 590 |
| 2022 | 449 |
| 2023 | 377 |
| 2024 | 314 |
| 2025 | 265 |
| 2026 | 185 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,846 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 1,264 | 38.2 | 36.3 | 45,142 |
| renal failureSignal | 694 | 11.9 | 11.0 | 6,898 |
| acute kidney injurySignal | 716 | 10.6 | 9.9 | 6,240 |
| gastrooesophageal reflux diseaseSignal | 369 | 10.4 | 9.4 | 3,121 |
| vomitingSignal | 493 | 2.4 | 2.2 | 397 |
| dyspnoeaSignal | 507 | 2.0 | 1.9 | 268 |
| nausea | 698 | 2.0 | 1.9 | 357 |
| fatigue | 606 | 1.8 | 1.6 | 205 |
| dizziness | 388 | 1.8 | 1.6 | 129 |
| pain | 439 | 1.6 | 1.5 | 105 |
| diarrhoea | 454 | 1.6 | 1.5 | 102 |
| headache | 373 | 1.3 | 1.2 | 33 |
| death | 403 | 1.1 | 1.0 | 1 |
| off label use | 387 | 1.0 | 0.9 | 0 |
| drug ineffective | 510 | 0.9 | 0.8 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.